Concepts (242)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 20 | 2020 | 553 | 1.660 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 11 | 2017 | 244 | 0.970 |
Why?
|
| Thoracotomy | 4 | 2016 | 29 | 0.760 |
Why?
|
| Pneumonectomy | 5 | 2020 | 77 | 0.690 |
Why?
|
| Esophageal Neoplasms | 3 | 2015 | 54 | 0.590 |
Why?
|
| Thoracic Surgery, Video-Assisted | 3 | 2020 | 22 | 0.550 |
Why?
|
| Adenocarcinoma | 7 | 2015 | 147 | 0.540 |
Why?
|
| Unnecessary Procedures | 2 | 2019 | 30 | 0.520 |
Why?
|
| Biomarkers, Tumor | 5 | 2015 | 202 | 0.490 |
Why?
|
| Esophagectomy | 2 | 2011 | 24 | 0.460 |
Why?
|
| Barrett Esophagus | 4 | 2015 | 16 | 0.460 |
Why?
|
| Catheter Ablation | 4 | 2015 | 72 | 0.430 |
Why?
|
| Esophageal Diseases | 1 | 2011 | 4 | 0.380 |
Why?
|
| Jejunostomy | 1 | 2011 | 9 | 0.370 |
Why?
|
| Aged | 26 | 2019 | 9334 | 0.370 |
Why?
|
| Enteral Nutrition | 1 | 2011 | 65 | 0.360 |
Why?
|
| Abnormalities, Drug-Induced | 4 | 2016 | 6 | 0.350 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2017 | 206 | 0.340 |
Why?
|
| Neoplasm Staging | 12 | 2019 | 371 | 0.330 |
Why?
|
| Empyema, Pleural | 1 | 2009 | 1 | 0.320 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2009 | 4 | 0.320 |
Why?
|
| Male | 29 | 2019 | 15400 | 0.320 |
Why?
|
| Intraoperative Complications | 1 | 2009 | 67 | 0.310 |
Why?
|
| Female | 30 | 2019 | 15818 | 0.300 |
Why?
|
| Surgical Wound Infection | 1 | 2009 | 88 | 0.300 |
Why?
|
| Positron-Emission Tomography | 3 | 2011 | 90 | 0.290 |
Why?
|
| Echinocandins | 3 | 2012 | 6 | 0.290 |
Why?
|
| Postoperative Complications | 4 | 2016 | 934 | 0.290 |
Why?
|
| Drainage | 2 | 2009 | 49 | 0.280 |
Why?
|
| Toxicity Tests | 4 | 2016 | 9 | 0.280 |
Why?
|
| Embryonic Development | 3 | 2016 | 6 | 0.260 |
Why?
|
| Middle Aged | 20 | 2017 | 9316 | 0.250 |
Why?
|
| Retrospective Studies | 11 | 2017 | 3612 | 0.250 |
Why?
|
| Humans | 32 | 2020 | 28560 | 0.240 |
Why?
|
| Embryo, Mammalian | 2 | 2016 | 24 | 0.230 |
Why?
|
| Solitary Pulmonary Nodule | 2 | 2015 | 15 | 0.230 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 177 | 0.220 |
Why?
|
| Bronchoscopy | 3 | 2019 | 34 | 0.210 |
Why?
|
| Pleurodesis | 1 | 2003 | 1 | 0.210 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2003 | 4 | 0.210 |
Why?
|
| Prognosis | 6 | 2017 | 826 | 0.210 |
Why?
|
| Consensus | 2 | 2020 | 98 | 0.200 |
Why?
|
| Aged, 80 and over | 12 | 2017 | 4894 | 0.200 |
Why?
|
| Radiosurgery | 3 | 2011 | 38 | 0.190 |
Why?
|
| Treatment Outcome | 11 | 2017 | 3620 | 0.190 |
Why?
|
| Antifungal Agents | 2 | 2012 | 43 | 0.190 |
Why?
|
| Survival Analysis | 5 | 2017 | 267 | 0.180 |
Why?
|
| Simulation Training | 1 | 2020 | 38 | 0.170 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 77 | 0.170 |
Why?
|
| Cohort Studies | 4 | 2017 | 1940 | 0.160 |
Why?
|
| Computer Simulation | 1 | 2020 | 205 | 0.160 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 9 | 0.160 |
Why?
|
| Surgeons | 1 | 2020 | 89 | 0.160 |
Why?
|
| False Positive Reactions | 1 | 2019 | 36 | 0.160 |
Why?
|
| Fetal Development | 2 | 2016 | 3 | 0.160 |
Why?
|
| Registries | 4 | 2015 | 188 | 0.150 |
Why?
|
| Fetus | 2 | 2016 | 41 | 0.150 |
Why?
|
| Neovascularization, Pathologic | 2 | 2015 | 36 | 0.150 |
Why?
|
| Bone and Bones | 2 | 2016 | 120 | 0.140 |
Why?
|
| Length of Stay | 3 | 2016 | 328 | 0.140 |
Why?
|
| Tracheomalacia | 1 | 2017 | 4 | 0.140 |
Why?
|
| Tracheal Stenosis | 1 | 2017 | 6 | 0.140 |
Why?
|
| Silicones | 1 | 2017 | 12 | 0.140 |
Why?
|
| Risk Assessment | 4 | 2017 | 677 | 0.140 |
Why?
|
| Airway Obstruction | 1 | 2017 | 20 | 0.140 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 331 | 0.140 |
Why?
|
| Clinical Competence | 2 | 2020 | 249 | 0.140 |
Why?
|
| Mutagenicity Tests | 1 | 2016 | 1 | 0.140 |
Why?
|
| Teratogens | 1 | 2016 | 1 | 0.140 |
Why?
|
| Hazardous Substances | 1 | 2016 | 2 | 0.140 |
Why?
|
| Pharmaceutical Preparations | 1 | 2016 | 11 | 0.130 |
Why?
|
| Stents | 1 | 2017 | 86 | 0.130 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2014 | 59 | 0.130 |
Why?
|
| Models, Animal | 1 | 2016 | 120 | 0.130 |
Why?
|
| Disease Progression | 4 | 2014 | 722 | 0.130 |
Why?
|
| Developmental Biology | 1 | 2016 | 1 | 0.130 |
Why?
|
| Ribs | 1 | 2016 | 15 | 0.130 |
Why?
|
| Thoracic Wall | 1 | 2016 | 12 | 0.130 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 519 | 0.130 |
Why?
|
| Metformin | 1 | 2016 | 20 | 0.130 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 40 | 0.130 |
Why?
|
| X-Ray Microtomography | 1 | 2016 | 88 | 0.120 |
Why?
|
| Esophagoscopy | 1 | 2015 | 15 | 0.120 |
Why?
|
| Animals | 8 | 2016 | 3812 | 0.120 |
Why?
|
| Learning Curve | 1 | 2015 | 17 | 0.120 |
Why?
|
| Rats | 5 | 2016 | 686 | 0.120 |
Why?
|
| Thoracoscopy | 2 | 2019 | 23 | 0.120 |
Why?
|
| Cytokines | 2 | 2014 | 231 | 0.120 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2014 | 10 | 0.120 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2014 | 10 | 0.120 |
Why?
|
| Tumor Burden | 3 | 2010 | 28 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 179 | 0.110 |
Why?
|
| Prosthesis Failure | 1 | 2017 | 539 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 191 | 0.110 |
Why?
|
| Intubation, Intratracheal | 2 | 2016 | 99 | 0.110 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 13 | 0.100 |
Why?
|
| Research Design | 2 | 2012 | 208 | 0.100 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2013 | 12 | 0.100 |
Why?
|
| Fundoplication | 1 | 2012 | 22 | 0.100 |
Why?
|
| Predictive Value of Tests | 4 | 2016 | 496 | 0.100 |
Why?
|
| Gastroesophageal Reflux | 1 | 2012 | 27 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 373 | 0.100 |
Why?
|
| Immunoassay | 1 | 2012 | 40 | 0.100 |
Why?
|
| Nitriles | 1 | 2012 | 14 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2012 | 22 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2016 | 352 | 0.100 |
Why?
|
| Triazoles | 1 | 2012 | 29 | 0.100 |
Why?
|
| Disease-Free Survival | 3 | 2017 | 177 | 0.100 |
Why?
|
| Adult | 8 | 2017 | 8168 | 0.100 |
Why?
|
| Fistula | 1 | 2011 | 3 | 0.090 |
Why?
|
| Gastric Fistula | 1 | 2011 | 5 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2015 | 772 | 0.090 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2011 | 7 | 0.090 |
Why?
|
| Nutrition Assessment | 1 | 2011 | 44 | 0.090 |
Why?
|
| Hospitals, Community | 1 | 2011 | 14 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2012 | 58 | 0.090 |
Why?
|
| Behavior, Animal | 1 | 2011 | 45 | 0.090 |
Why?
|
| Community-Institutional Relations | 1 | 2011 | 15 | 0.090 |
Why?
|
| Radiography, Interventional | 1 | 2011 | 23 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2011 | 42 | 0.090 |
Why?
|
| Algorithms | 3 | 2014 | 380 | 0.090 |
Why?
|
| Anticarcinogenic Agents | 1 | 2010 | 18 | 0.090 |
Why?
|
| Prospective Studies | 5 | 2015 | 1807 | 0.090 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2010 | 19 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2011 | 70 | 0.090 |
Why?
|
| Minority Groups | 1 | 2011 | 87 | 0.090 |
Why?
|
| Bronchi | 1 | 2010 | 12 | 0.090 |
Why?
|
| Risk Factors | 5 | 2015 | 2412 | 0.090 |
Why?
|
| Age Factors | 2 | 2009 | 788 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 239 | 0.080 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2009 | 9 | 0.080 |
Why?
|
| Patient Selection | 1 | 2011 | 207 | 0.080 |
Why?
|
| Probability | 1 | 2009 | 92 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 199 | 0.080 |
Why?
|
| Trachea | 1 | 2010 | 49 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 130 | 0.080 |
Why?
|
| Thoracic Surgery | 1 | 2009 | 27 | 0.080 |
Why?
|
| Area Under Curve | 3 | 2014 | 62 | 0.080 |
Why?
|
| Survival Rate | 2 | 2010 | 356 | 0.080 |
Why?
|
| Staphylococcus aureus | 1 | 2009 | 68 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2011 | 465 | 0.080 |
Why?
|
| Recurrence | 2 | 2014 | 322 | 0.070 |
Why?
|
| Neoplasms | 1 | 2011 | 240 | 0.070 |
Why?
|
| United States | 4 | 2015 | 2197 | 0.070 |
Why?
|
| Rats, Inbred F344 | 3 | 2012 | 35 | 0.070 |
Why?
|
| Laparoscopy | 1 | 2009 | 198 | 0.070 |
Why?
|
| Staphylococcal Infections | 1 | 2009 | 158 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 89 | 0.070 |
Why?
|
| Rabbits | 2 | 2016 | 193 | 0.070 |
Why?
|
| Lung | 2 | 2005 | 170 | 0.060 |
Why?
|
| Time Factors | 3 | 2015 | 1501 | 0.060 |
Why?
|
| Pregnancy | 3 | 2012 | 341 | 0.060 |
Why?
|
| Pneumonia | 2 | 2019 | 77 | 0.060 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2009 | 318 | 0.060 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 2005 | 2 | 0.060 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2005 | 6 | 0.060 |
Why?
|
| Logistic Models | 2 | 2015 | 396 | 0.060 |
Why?
|
| ROC Curve | 2 | 2014 | 144 | 0.050 |
Why?
|
| Catheters, Indwelling | 1 | 2003 | 24 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2014 | 1863 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 735 | 0.050 |
Why?
|
| Proton Pump Inhibitors | 2 | 2012 | 14 | 0.050 |
Why?
|
| Incidence | 2 | 2015 | 774 | 0.050 |
Why?
|
| Brain | 1 | 2011 | 1695 | 0.050 |
Why?
|
| Mediastinoscopy | 1 | 2019 | 7 | 0.040 |
Why?
|
| Sex Factors | 2 | 2012 | 476 | 0.040 |
Why?
|
| Reoperation | 2 | 2015 | 917 | 0.040 |
Why?
|
| Radiography | 2 | 2013 | 651 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 104 | 0.040 |
Why?
|
| Dilatation | 1 | 2017 | 10 | 0.040 |
Why?
|
| Young Adult | 2 | 2014 | 2102 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 21 | 0.030 |
Why?
|
| Pneumonia, Bacterial | 1 | 2016 | 11 | 0.030 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2016 | 9 | 0.030 |
Why?
|
| Tracheostomy | 1 | 2016 | 27 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 104 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 68 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2015 | 17 | 0.030 |
Why?
|
| Protective Factors | 1 | 2015 | 26 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2015 | 8 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 358 | 0.030 |
Why?
|
| Hospitals, Low-Volume | 1 | 2015 | 6 | 0.030 |
Why?
|
| Hospitals, High-Volume | 1 | 2015 | 8 | 0.030 |
Why?
|
| Remission Induction | 1 | 2015 | 90 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 146 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 64 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 352 | 0.030 |
Why?
|
| Minnesota | 1 | 2014 | 9 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 137 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 268 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 255 | 0.030 |
Why?
|
| Biomarkers | 1 | 2017 | 601 | 0.030 |
Why?
|
| Illinois | 1 | 2014 | 247 | 0.030 |
Why?
|
| Chemokine CCL3 | 1 | 2013 | 9 | 0.030 |
Why?
|
| Granuloma | 1 | 2013 | 15 | 0.030 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2013 | 15 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 10 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2013 | 20 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2013 | 27 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2013 | 79 | 0.030 |
Why?
|
| Maternal Exposure | 1 | 2012 | 1 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 52 | 0.020 |
Why?
|
| Voriconazole | 1 | 2012 | 12 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 90 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2012 | 25 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2012 | 36 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2012 | 33 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 31 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2012 | 46 | 0.020 |
Why?
|
| Cesarean Section | 1 | 2012 | 30 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 192 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 111 | 0.020 |
Why?
|
| Hematemesis | 1 | 2011 | 2 | 0.020 |
Why?
|
| Stomach Ulcer | 1 | 2011 | 4 | 0.020 |
Why?
|
| Esophageal Perforation | 1 | 2011 | 8 | 0.020 |
Why?
|
| Body Weight | 1 | 2012 | 146 | 0.020 |
Why?
|
| Candidiasis | 1 | 2011 | 22 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 57 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2011 | 20 | 0.020 |
Why?
|
| Michigan | 1 | 2011 | 18 | 0.020 |
Why?
|
| Osteogenesis | 1 | 2012 | 113 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2012 | 92 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 82 | 0.020 |
Why?
|
| Contrast Media | 1 | 2011 | 75 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2011 | 54 | 0.020 |
Why?
|
| Organogenesis | 1 | 2010 | 2 | 0.020 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2010 | 7 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2010 | 25 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2010 | 19 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 137 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 85 | 0.020 |
Why?
|
| Rupture | 1 | 2010 | 114 | 0.020 |
Why?
|
| Hospitalization | 1 | 2012 | 322 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 501 | 0.020 |
Why?
|
| Motor Activity | 1 | 2011 | 332 | 0.020 |
Why?
|
| Mice | 1 | 2012 | 1465 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2007 | 117 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2007 | 68 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 139 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 309 | 0.010 |
Why?
|
| Cognition | 1 | 2011 | 1378 | 0.010 |
Why?
|
| Aging | 1 | 2012 | 1576 | 0.010 |
Why?
|